empanelment of drug testing laboratories - Kerala Medical Services ...

More documents

Recommendations

Info

5.5.7 No interest will be paid for the EMD submitted. 5.5.8 The EMD will be forfeited, if an offerer; 5.5.8.1 Misrepresents facts or submit false / fake documents during the EOI process. 5.5.8.2 If the offerer willfully violates any terms and conditions of the EOI documents. 5.5.8.3 If the offerer withdraws its bid after the opening of EOI document. 5.5.8.4 A successful offerer fails to sign the contract after issuance of Letter Of Intent. 5.5.8.5. Fails to furnish performance security after issuance of Letter Of Intent. 5.5.8.6. If the EOI offer is rejected on the basis of the non satisfactory inspection report of the Quality control facilities of the firm. 5.6 Period of Validity of EOI 5.6.1 The offers must remain valid for two years. An offer for a shorter period shall be rejected by the Corporation as non-responsive. 5.6.2 Withdrawal or non-compliance of agreed terms and conditions after the execution of agreement will lead to invoking of penal provisions and may also lead to black listing / debarring of the successful offerer as per the procedure detailed in clause 5.34, for a period upto 3 years, immediately succeeding the EOI agreement year and the offerer will be ineligible to participate in any of the empanelment / tender of the Corporation for a period upto 3 year. 5.7 Pre Offer Meeting 5.7.1 Date of pre-offer meeting is mentioned in Section III. 5.7.2 Pre-offer meeting is called by the Corporation to explain briefly about the requirements as well as the terms and conditions of the EOI document and to get the views of the prospective offerers, as part of ensuring transparency in the EOI process. 5.7.3 It is an opportunity for the prospective offerer to obtain all the details about the offered items, conditions governing the offer and also to get the explanation of any ambiguous condition that may be present in the EOI document. KMSCL: EOI for Empanelment of Drug testing Laboratories Page 13
5.7.4 It is also an opportunity for the Corporation to assess the market and obtain feedback on the current developments in drug testing, so as to make amendments in the EOI document on the basis of expert advice. 5.7.5 All prospective offerers can attend the pre offer meeting. The venue, date and time is indicated in Section III. 5.7.6 Failure to attend the pre-offer meeting will not be a disqualification, but a loss of opportunity for the prospective offerers to understand the EOI conditions. 5.7.7 Filled up EOI will be accepted only after the date of pre offer meeting. 5.8 Amendment of EOI documents: 5.8.1 At any time prior to the dead line for submission of EOI, the EOI Inviting Authority may, for any reason, modify the EOI document by amendment. 5.8.2 The amendment shall be published in the website of the Corporation or notified by fax/email to all prospective offerers who have purchased the EOI document, for which the email, fax no of the purchaser of the EOI document shall be submitted to the EOI inviting authority and such amendments, shall be binding on them thereafter. 5.8.3 The Corporation shall not be responsible for failure to inform the prospective offerers because of technical issues, wrong fax number or email ID etc. Purchasers of EOI documents are requested to browse the website of the Corporation for information / general notices /amendments to EOI document etc on a day to day basis till the EOI is concluded. 5.9 EOI Process The EOI Process is divided into two: 5.9.1 Scrutiny of technical documents submitted before the schedule date and time. 5.9.2 Inspection of the shortlisted lab by a technical committee on behalf of the Corporation and selection of the lab. 5.10 Contents of the EOI documents 5.10.1 The offerer must submit the following documents in a sealed cover 5.10.2 Checklist (Annexure –I) for the list of documents enclosed with their page Nos. The documents should be serially numbered and arranged as per KMSCL: EOI for Empanelment of Drug testing Laboratories Page 14
Page 1 and 2: KERALA MEDICAL SERVICES CORPORATION
Page 3 and 4: SECTION I INTRODUCTION 1.1. The Ker
Page 5 and 6: SECTION - II INVITATION OF EXPRESSI
Page 7 and 8: 2.16. The EOI Responder must submit
Page 9 and 10: 4.1 Time Limits Prescribed: SECTION
Page 11 and 12: 5.1 Contents of the EOI Document: S
Page 13: 5.4.10 A prospective offerer requir
Page 17 and 18: 5.10.17 Declaration in the Proforma
Page 19 and 20: opening of the envelopes before the
Page 21 and 22: 5.17.7 The availability of technica
Page 23 and 24: 5.22 Notification of Award/Letter o
Page 25 and 26: 5.24.6 Corporation will release the
Page 27 and 28: egard shall be in writing and the C
Page 29 and 30: testing fees at artificial non-comp
Page 31 and 32: 5.33.1 Nothing contained in this Co
Page 33 and 34: ANNEXURES KMSCL: EOI for Empanelmen
Page 35 and 36: EOI Cost EMD 12. Annexure VII - Det
Page 37 and 38: No.4.2.8 (Provide contact details l
Page 39 and 40: ANNEXURE- II (b) Ref. Clause No.5.1
Page 41 and 42: ANNEXURE-III Ref. Clause No.5.10.3
Page 43 and 44: PROFORMA FOR PERFORMANCE STATEMENT
Page 45 and 46: DECLARATION FORM ANNEXURE-VI Ref. C
Page 47 and 48: CONSENT LETTER OF THE OFFERER From,
Page 49 and 50: liability under this guarantee and
Page 51 and 52: And whereas the Laboratory has depo
Page 53 and 54: which bank details shall be furnish
Page 55 and 56: 14. In the event of any disputes be
Page 57 and 58: 39 D04017 Bupivacaine In Dextrose I
Page 59 and 60: 101 D18007/ Electrolyte P(Multi Inj
Page 61 and 62: 160 D02025 Metronidazole IP. Inj 5
Page 63 and 64: 228 D03001 Theophylline and Etophyl
Page 65 and 66:
40 S27050 Endotracheal Tube 5.0 1 U
Page 67 and 68:
19 S27004 Hypo Allergic Acrylic Pap
Page 69 and 70:
25 S27572 26 S27531 27 S27574 28 S2
Page 71 and 72:
DETAILS OF LABRATES FOR THE DRUGS A
Page 73 and 74:
45 D11006 Cabergoline tab Tab 0.5mg
Page 75 and 76:
88 D01028 Diclofenac sodium Gel Gel
Page 77 and 78:
126 D02074 Hpylori kit Each combi p
Page 79 and 80:
163 D04026 Lignocaine topical Spray
Page 81 and 82:
207 D24052 Octreotide Inj Inj 50 mc
Page 83 and 84:
255 D08028 Pyrantel Palmoate Syrup
Page 85:
302 D20037 Ursodeoxycholic Acid Tab
show all

empanelment of drug testing laboratories - Kerala Medical Services ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?